The priority review granted Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) comes in the wake of a string of problems affecting the drug maker. This includes losing four patents that protected Copaxone, a drug for treating multiple sclerosis. The company's chief executive officer, Erez Vigodman also resigned following a bribery scandal in Mexico, Ukraine, and Russia which also saw the U.S. Department of Justice open an investigation into the matter.